type 1 diabetes

type 1 diabetes
Name	type 1 diabetes
Synonyms	Insulin-dependent diabetes, juvenile diabetes
Caption	An insulin pen, a primary tool for management.
Field	Endocrinology
Symptoms	Frequent urination, increased thirst, unexplained weight loss
Complications	Diabetic ketoacidosis, cardiovascular disease, retinopathy
Onset	Often in childhood or adolescence
Duration	Lifelong
Causes	Autoimmune destruction of pancreatic islets
Risks	Genetic predisposition, certain viral infections
Diagnosis	Blood tests for glycated hemoglobin and autoantibodies
Treatment	Insulin therapy, blood glucose monitoring
Frequency	~5-10% of all diabetes cases

type 1 diabetes is a chronic autoimmune condition characterized by the body's inability to produce insulin due to the immune-mediated destruction of insulin-producing beta cells in the pancreas. This leads to a lifelong dependence on exogenous insulin administration for survival. The condition often presents acutely, with a classic triad of symptoms, and requires meticulous daily management to prevent severe complications. Its etiology involves a complex interplay of genetic susceptibility and environmental triggers, distinguishing it fundamentally from other forms of diabetes mellitus.

Signs and symptoms

The initial presentation often includes the classic symptoms of polyuria, polydipsia, and unexplained weight loss, which can progress rapidly. Patients may experience increased hunger, blurred vision, and profound fatigue. If undiagnosed, the condition can escalate to diabetic ketoacidosis, a medical emergency characterized by Kussmaul respirations, fruity-smelling breath, abdominal pain, and altered mental status. Long-term, poorly managed disease contributes to microvascular and macrovascular complications, including diabetic neuropathy, diabetic retinopathy, and an increased risk of atherosclerosis and stroke.

Causes and pathophysiology

The primary cause is an autoimmune attack on the pancreatic islets, specifically targeting the beta cells. This process is believed to be initiated in genetically susceptible individuals by environmental factors, with strong associations to human leukocyte antigen genotypes, particularly HLA-DR3 and HLA-DR4. Potential environmental triggers include certain viral infections, such as enteroviruses like Coxsackievirus B, and early dietary factors. The pathophysiology involves T lymphocytes infiltrating the islets of Langerhans, leading to insulitis and eventual beta cell loss, resulting in absolute insulin deficiency and dysregulation of glucagon secretion.

Diagnosis

Diagnosis is confirmed through blood tests demonstrating persistent hyperglycemia. Key criteria include a glycated hemoglobin level at or above 6.5%, a fasting plasma glucose of 126 mg/dL or higher, or a random plasma glucose over 200 mg/dL with classic symptoms. The presence of autoantibodies against islet cell antigens, such as glutamic acid decarboxylase antibodies, insulinoma-associated-2 antibodies, or zinc transporter 8 antibodies, helps differentiate it from type 2 diabetes. Testing for C-peptide levels, a marker of endogenous insulin production, typically shows low or undetectable levels.

Management

Management is centered on replacing the absent hormone through insulin therapy, delivered via multiple daily injections or insulin pump technology. Regimens often involve a combination of basal insulin and bolus insulin. Continuous blood glucose monitoring systems and, increasingly, automated insulin delivery systems like the Medtronic MiniMed or Tandem Diabetes Care t:slim are used to optimize control. The treatment goal is to maintain glycated hemoglobin levels as close to normal as possible to prevent complications, guided by standards from organizations like the American Diabetes Association. Education through diabetes self-management education and support programs is critical.

Epidemiology

It accounts for approximately 5-10% of all diabetes cases worldwide. Incidence rates vary significantly by geography and ethnicity, with high rates reported in Finland, Sardinia, and Sweden, and lower rates in East Asia. The typical age of onset is in childhood or adolescence, though it can develop at any age, a form sometimes termed latent autoimmune diabetes in adults. Epidemiological studies, such as the Diabetes Autoimmunity Study in the Young, track the natural history. There is evidence of a gradual increase in incidence globally, suggesting changing environmental influences.

History

The condition was described as a fatal wasting disease in ancient texts, including the Ebers Papyrus. In the early 20th century, pivotal work by Frederick Banting and Charles Best at the University of Toronto, under the direction of John Macleod, led to the discovery and purification of insulin from pancreatic islets. The first successful treatment was administered to Leonard Thompson in Toronto General Hospital in 1922, a breakthrough recognized with the Nobel Prize in Physiology or Medicine awarded to Banting and Macleod in 1923. Subsequent milestones include the development of the radioimmunoassay by Rosalyn Yalow, the introduction of human insulin, and the Diabetes Control and Complications Trial.

Category:Autoimmune diseases Category:Diabetes Category:Endocrine diseases